Quantitation of small intestinal permeability during normal human drug absorption

BMC Pharmacology and Toxicology

Volumn 14, Issue , 2013, Pages

  Levitt, David G ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DOMPERIDONE; PARACETAMOL; RISEDRONIC ACID; DRUG;

ARTICLE; AVERAGED MODEL; DIFFUSION CONVECTION MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ELIXIR; HUMAN; HUMAN EXPERIMENT; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; MODEL; NORMAL HUMAN; PH; SMALL INTESTINE PERMEABILITY; STOMACH EMPTYING; VALIDITY; ABSORPTION; BIOLOGICAL MODEL; METABOLISM; PERMEABILITY; SMALL INTESTINE;

ABSORPTION; HUMANS; INTESTINAL ABSORPTION; INTESTINE, SMALL; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS;

EID: 84880624123     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-14-34     Document Type: Article

References (61)

1. Egan WJ, Lauri G. Prediction of intestinal permeability. Adv Drug Deliv Rev 2002, 54(3):273-289. 10.1016/S0169-409X(02)00004-2, 11922948.
2. Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Butina D, Beck G, Sherborne B, Cooper I, et al. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci 2001, 90(6):749-784. 10.1002/jps.1031, 11357178.
3. Amidon KS, Langguth P, Lennernas H, Yu L, Amidon GL. Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy. Clin Pharmacol Ther 2011, 90(3):467-470. 10.1038/clpt.2011.109, 3228645, 21775984.
4. Dahan A, Lennernas H, Amidon GL. The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Molecular pharmaceutics 2012, 9(6):1847-1851. 10.1021/mp300140h, 3482341, 22524707.
5. Soderholm JD, Olaison G, Kald A, Tagesson C, Sjodahl R. Absorption profiles for polyethylene glycols after regional jejunal perfusion and oral load in healthy humans. Dig Dis Sci 1997, 42(4):853-857. 10.1023/A:1018836803254, 9125661.
6. Levitt DG. The use of a physiologically based pharmacokinetic model to evaluate deconvolution measurements of systemic absorption. BMC Clin Pharmacol 2003, 3:1. 153531, 12659643.
7. Levitt DG. PKQuest_Java: free, interactive physiologically based pharmacokinetic software package and tutorial. BMC research notes 2009, 2:158. 10.1186/1756-0500-2-158, 2728517, 19656378.
8. Sparacino G, Pillonetto G, Capello M, De Nicolao G, Cobelli C. WINSTODEC: a stochastic deconvolution interactive program for physiological and pharmacokinetic systems. Comput Methods Programs Biomed 2002, 67(1):67-77. 10.1016/S0169-2607(00)00151-6, 11750948.
9. Verotta D. Estimation and model selection in constrained deconvolution. Ann Biomed Eng 1993, 21(6):605-620. 10.1007/BF02368641, 8116913.
10. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001, 50(Suppl 1):S41-S67.
11. Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999, 186(2):119-125. 10.1016/S0378-5173(99)00147-7, 10486429.
12. Ni PF HONFH, Fox JL, Leuenberger H, Higuchi HI. Theoretical model studies of intestinal drug absorption V. Non-steady-state fluid flow and absorption. Int J Pharm 1980, 5:33-47.
13. Collins PJ, Horowitz M, Cook DJ, Harding PE, Shearman DJ. Gastric emptying in normal subjects-a reproducible technique using a single scintillation camera and computer system. Gut 1983, 24(12):1117-1125. 10.1136/gut.24.12.1117, 1420248, 6642275.
14. George JD. New clinical method for measuring the rate of gastric emptying: the double sampling test meal. Gut 1968, 9(2):237-242. 10.1136/gut.9.2.237, 1552567, 4871724.
15. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995, 58(5):492-497. 10.1016/0009-9236(95)90168-X, 7586942.
16. Press WH, Teukolsky SA, Vetterling WT, Flannery BP. Numerical Recipes in C 1992, Cambridge: Cambridge University Press, 2.
17. Poulin P, Schoenlein K, Theil FP. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 2001, 90(4):436-447. 10.1002/1520-6017(200104)90:4<436::AID-JPS1002>3.0.CO;2-P, 11170034.
18. Lennernas H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 2007, 37(10-11):1015-1051.
19. Miller MS, Galligan JJ, Burks TF. Accurate measurement of intestinal transit in the rat. J Pharmacol Methods 1981, 6(3):211-217. 10.1016/0160-5402(81)90110-8, 7329070.
20. Yu LX, Amidon GL. Characterization of small intestinal transit time distribution in humans. Int J Pharm 1998, 171(2):157-163.
21. Caride VJ, Prokop EK, Troncale FJ, Buddoura W, Winchenbach K, McCallum RW. Scintigraphic determination of small intestinal transit time: comparison with the hydrogen breath technique. Gastroenterology 1984, 86(4):714-720.
22. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986, 27(8):886-892. 10.1136/gut.27.8.886, 1433369, 3732895.
23. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 2007, 8(7):676-684. 10.2174/138920007782109733, 17979655.
24. Clements JA, Heading RC, Nimmo WS, Prescott LF. Kinetics of acetaminophen absorption and gastric emptying in man. Clin Pharmacol Ther 1978, 24(4):420-431.
25. Heading RC, Nimmo J, Prescott LF, Tothill P. The dependence of paracetamol absorption on the rate of gastric emptying. Br J Pharmacol 1973, 47(2):415-421. 10.1111/j.1476-5381.1973.tb08339.x, 1776534, 4722050.
26. Ogungbenro K, Vasist L, Maclaren R, Dukes G, Young M, Aarons L. A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. Pharm Res 2011, 28(2):394-404. 10.1007/s11095-010-0290-8, 20949310.
27. Ameer B, Divoll M, Abernethy DR, Greenblatt DJ, Shargel L. Absolute and relative bioavailability of oral acetaminophen preparations. J Pharm Sci 1983, 72(8):955-958. 10.1002/jps.2600720832, 6688635.
28. Divoll M, Ameer B, Abernethy DR, Greenblatt DJ. Age does not alter acetaminophen absorption. J Am Geriatr Soc 1982, 30(4):240-244.
29. Eandi M, Viano I, Ricci Gamalero S. Absolute bioavailability of paracetamol after oral or rectal administration in healthy volunteers. Arzneimittelforschung 1984, 34(8):903-907.
30. Mitchell DY, Barr WH, Eusebio RA, Stevens KA, Duke FP, Russell DA, Nesbitt JD, Powell JH, Thompson GA. Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharm Res 2001, 18(2):166-170. 10.1023/A:1011024200280, 11405286.
31. Hui YF, Kolars J, Hu Z, Fleisher D. Intestinal clearance of H2-antagonists. Biochem Pharmacol 1994, 48(2):229-231. 10.1016/0006-2952(94)90091-4, 7914403.
32. Walkenstein SS, Dubb JW, Randolph WC, Westlake WJ, Stote RM, Intoccia AP. Bioavailability of cimetidine in man. Gastroenterology 1978, 74(2 Pt 2):360-365.
33. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 1981, 6(1):61-70. 10.1007/BF03189516, 7250152.
34. Gray VA, Dressman JB. Change of pH requirement for simulated intestinal fluid TS. Pharmacopeial Forum 1996, 22(1):1943-1945.
35. Ovesen L, Bendtsen F, Tage-Jensen U, Pedersen NT, Gram BR, Rune SJ. Intraluminal pH in the stomach, duodenum, and proximal jejunum in normal subjects and patients with exocrine pancreatic insufficiency. Gastroenterology 1986, 90(4):958-962.
36. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988, 29(8):1035-1041. 10.1136/gut.29.8.1035, 1433896, 3410329.
37. Lalezari D. Gastrointestinal pH profile in subjects with irritible syndrome. Ann Gastroenterol 2012, 25(4):1-5.
38. Avdeef A. Absorption and drug development. Solubility, permeability and charge state 2003, Hoboken, New Jersey: John Wiley and Sons,Inc.
39. Kramer SD. Absorption prediction from physicochemical parameters. Pharm Sci Technology Today 1999, 2(9):373-380.
40. Pauli-Magnus C, Murdter T, Godel A, Mettang T, Eichelbaum M, Klotz U, Fromm MF. P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol 2001, 363(3):337-343. 10.1007/s002100000354, 11284449.
41. Dahan A, Amidon GL. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res 2009, 26(4):883-892. 10.1007/s11095-008-9789-7, 19048359.
42. Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, Stellbrink HJ, Faetkenheuer G, Taubert D. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos 2008, 36(8):1616-1623. 10.1124/dmd.108.020826, 18490433.
43. Levitt DG, Hakim AA, Lifson N. Evaluation of components of transport of sugars by dog jejunum in vivo. Am J Physiol 1969, 217(3):777-783.
44. Rolston DD, Mathan VI. Xylose transport in the human jejunum. Dig Dis Sci 1989, 34(4):553-558. 10.1007/BF01536332, 2702886.
45. Csaky TZ, Ho PM, Csaky TZ, Ho PM. Intestinal transport of D-xylose. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine (New York, NY) 1965, 120(2):403-408.
46. Tsuda M, Terada T, Irie M, Katsura T, Niida A, Tomita K, Fujii N, Inui K. Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther 2006, 318(1):455-460. 10.1124/jpet.106.102830, 16597710.
47. Rowland M. Influence of route of administration on drug availability. J Pharm Sci 1972, 61(1):70-74. 10.1002/jps.2600610111, 5019220.
48. Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV. Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur J Clin Pharmacol 1988, 35(3):287-294. 10.1007/BF00558267, 3181281.
49. Hogben CA, Tocco DJ, Brodie BB, Schanker LS. On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther 1959, 125(4):275-282.
50. Levitt MD, Strocchi A, Levitt DG. Human jejunal unstirred layer: evidence for extremely efficient luminal stirring. Am J Physiol 1992, 262(3 Pt 1):G593-G596.
51. Rechkemmer G, Wahl M, Kuschinsky W, von Engelhardt W. pH-microclimate at the luminal surface of the intestinal mucosa of guinea pig and rat. Pflugers Arch 1986, 407(1):33-40. 10.1007/BF00580717, 3737380.
52. Takanaga H, Tamai I, Tsuji A. pH-dependent and carrier-mediated transport of salicylic acid across Caco-2 cells. J Pharm Pharmacol 1994, 46(7):567-570. 10.1111/j.2042-7158.1994.tb03858.x, 7996384.
53. Tamai I, Takanaga H, Maeda H, Yabuuchi H, Sai Y, Suzuki Y, Tsuji A. Intestinal brush-border membrane transport of monocarboxylic acids mediated by proton-coupled transport and anion antiport mechanisms. J Pharm Pharmacol 1997, 49(1):108-112. 10.1111/j.2042-7158.1997.tb06762.x, 9120761.
54. Takagi M, Taki Y, Sakane T, Nadai T, Sezaki H, Oku N, Yamashita S. A new interpretation of salicylic acid transport across the lipid bilayer: implications of pH-dependent but not carrier-mediated absorption from the gastrointestinal tract. J Pharmacol Exp Ther 1998, 285(3):1175-1180.
55. Fagerholm U, Lennernas H. Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and it importance in oral drug absorption. Eur J Pharm Sci 1995, 3:247-253.
56. Mackenzie NM. Comparison of the metabolic activities of enterocytes isolated from different regions of the small intestine of the neonate. Biol Neonate 1985, 48(5):257-268. 10.1159/000242179, 3933580.
57. Lennernas H. Human intestinal permeability. J Pharm Sci 1998, 87(4):403-410. 10.1021/js970332a, 9548891.
58. Knutson T, Fridblom P, Ahlstrom H, Magnusson A, Tannergren C, Lennernas H. Increased understanding of intestinal drug permeability determined by the LOC-I-GUT approach using multislice computed tomography. Mol Pharm 2009, 6(1):2-10. 10.1021/mp800145r, 19248228.
59. Larregieu CA, Benet LZ. Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use caco-2 as a surrogate for human intestinal permeability measurements. AAPS J 2013, 15(2):483-497. 10.1208/s12248-013-9456-8, 23344793.
60. Thomas S, Brightman F, Gill H, Lee S, Pufong B. Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. J Pharm Sci 2008, 97(10):4557-4574. 10.1002/jps.21305, 18300298.
61. Hidalgo IJ, Hillgren KM, Grass GM, Borchardt RT. Characterization of the unstirred water layer in Caco-2 cell monolayers using a novel diffusion apparatus. Pharm Res 1991, 8(2):222-227. 10.1023/A:1015848205447, 2023871.